These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 6662623)

  • 21. Comparative pharmacokinetics, biodistribution, metabolism and hypoxia-dependent uptake of [18F]-EF3 and [18F]-MISO in rodent tumor models.
    Mahy P; De Bast M; de Groot T; Cheguillaume A; Gillart J; Haustermans K; Labar D; Grégoire V
    Radiother Oncol; 2008 Dec; 89(3):353-60. PubMed ID: 18649964
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The effect of prolonged high dose misonidazole on tumor response to radiation.
    McNally NJ; de Ronde J; Hinchliffe M
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1281-5. PubMed ID: 6469751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The labelling of EMT-6 tumours in BALB/C mice with 14C-misonidazole.
    Garrecht BM; Chapman JD
    Br J Radiol; 1983 Oct; 56(670):745-53. PubMed ID: 6616139
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Synthesis of [82Br]bromperidol and preliminary tissue distribution studies in the rat.
    Vincent SH; Shambhu MB; Digenis GA
    J Med Chem; 1980 Jan; 23(1):75-9. PubMed ID: 7359515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Regional [14C]misonidazole distribution in experimental RT-9 brain tumors.
    Horowitz M; Blasberg R; Molnar P; Strong J; Kornblith P; Pleasants R; Fenstermacher J
    Cancer Res; 1983 Aug; 43(8):3800-7. PubMed ID: 6861144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Evaluation of [131I]iodoerythronitroimidazole as a predictor for the radiosensitizing effect.
    Inoue T; Yang DJ; Wallace S; Cherif A; Tansey W; Kim EE; Hunter N; Milross CG; Milas L; Podoloff DA
    Anticancer Drugs; 1996 Nov; 7(8):858-65. PubMed ID: 8991190
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of diethyl maleate (DEM) on the radiosensitization by misonidazole (MISO) in experimental animal tumors].
    Ono K; Takahashi M; Nishidai T; Dodo Y; Abe M
    Nihon Igaku Hoshasen Gakkai Zasshi; 1984 Mar; 44(3):517-22. PubMed ID: 6462898
    [No Abstract]   [Full Text] [Related]  

  • 28. Effects of local hyperthermia on the pharmacokinetics of misonidazole in the anaesthetized mouse.
    Honess DJ; Workman P; Morgan JE; Bleehen NM
    Br J Cancer; 1980 Apr; 41(4):529-40. PubMed ID: 7387851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Depletion of glutathione in vivo as a method of improving the therapeutic ratio of misonidazole and SR 2508.
    Yu NY; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1265-9. PubMed ID: 6236185
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A comparative investigation of nimorazole and misonidazole as hypoxic radiosensitizers in a C3H mammary carcinoma in vivo.
    Overgaard J; Overgaard M; Nielsen OS; Pedersen AK; Timothy AR
    Br J Cancer; 1982 Dec; 46(6):904-11. PubMed ID: 7150484
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Myocardial imaging agents: synthesis, characterization, and evaluation of (Z)- and (Z,E)-18-[82Br]bromo-5-tellura-17-octadecenoic acids.
    Srivastava PC; Knapp FF; Callahan AP; Owen BA; Kabalka GW; Sastry KA
    J Med Chem; 1985 Apr; 28(4):408-13. PubMed ID: 3981533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacokinetics and toxicology of continuously infused nitroimidazoles.
    Eifel PJ; Brown JM
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1311-4. PubMed ID: 6236186
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modification of alkylating agent induced cell kill by 2-nitroimidazoles in unclamped and clamped SC 9L tumors.
    Wallen CA; Moore SK; Wheeler KT
    Int J Radiat Oncol Biol Phys; 1992; 22(4):727-30. PubMed ID: 1531976
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A new, potent 2-nitroimidazole nucleoside hypoxic cell radiosensitizer, RP170.
    Sasai K; Shibamoto Y; Takahashi M; Abe M; Wang J; Zhou L; Nishimoto S; Kagiya T
    Jpn J Cancer Res; 1989 Nov; 80(11):1113-8. PubMed ID: 2532634
    [TBL] [Abstract][Full Text] [Related]  

  • 35. KIH-802, an acetohydroxamic acid derivative of 2-nitroimidazole, as a new potent hypoxic cell radiosensitizer: radiosensitizing activity, acute toxicity, and pharmacokinetics.
    Sasai K; Shibamoto Y; Takahashi M; Zhou L; Hori H; Nagasawa H; Shibata T; Inayama S; Abe M
    Cancer Chemother Pharmacol; 1990; 26(2):112-6. PubMed ID: 2140730
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The pharmacokinetics in mice and dogs of nitroimidazole radiosensitizers and chemosensitizers more lipophilic than misonidazole.
    White R; Workman P; Owen L
    Int J Radiat Oncol Biol Phys; 1982; 8(3-4):473-6. PubMed ID: 7107369
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetic considerations in testing hypoxic cell radiosensitizers in mouse tumours.
    Brown JM; Yu NY; Workman P
    Br J Cancer; 1979 Mar; 39(3):310-20. PubMed ID: 465300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The effect of vitamin B6 on the neurotoxicity and pharmacology of desmethylmisonidazole and misonidazole: clinical and laboratory studies.
    Coleman CN; Hirst VK; Brown DM; Halsey J
    Int J Radiat Oncol Biol Phys; 1984 Aug; 10(8):1381-6. PubMed ID: 6469761
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Synthesis and in vivo evaluation of 2 high-affinity 76Br-labeled sigma2-receptor ligands.
    Rowland DJ; Tu Z; Xu J; Ponde D; Mach RH; Welch MJ
    J Nucl Med; 2006 Jun; 47(6):1041-8. PubMed ID: 16741315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
    Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
    J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.